# The Clinical Efficacy of Immunomodulators in RA Patients

> **NCT05626348** · PHASE4 · RECRUITING · sponsor: **Qilu Hospital of Shandong University** · enrollment: 400 (estimated)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Iguratimod
- **DRUG:** Methotrexate
- **DRUG:** Adalimumab Injection
- **DRUG:** Leflunomide
- **DRUG:** Hydroxychloroquine

## Key facts

- **NCT ID:** NCT05626348
- **Lead sponsor:** Qilu Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-22
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626348, "The Clinical Efficacy of Immunomodulators in RA Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05626348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*